Micardis 80 - Boehringer Ingelheim

Telmisartan’s therapeutic applications have broadened from hypertension management to oncology research, showing promising effects against cancer growth. In recent studies, telmisartan inhibited the proliferation of esophageal squamous cell carcinoma (ESCC) cells, primarily through cell-cycle arrest, which reduces the expression of growth-regulating proteins such as cyclin A2 and CDK2. Additionally, telmisartan decreased ErbB3 receptor levels, a protein crucial for cell proliferation and survival, suggesting its broader influence on tumor signaling pathways. These findings support telmisartan’s emerging role as a dual-action drug, offering cardiovascular benefits and potential as an antitumor agent, particularly for ESCC.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Micardis 80 by Boehringer Ingelheim, consult with your doctor or healthcare professional.